UTHR logo

United Therapeutics Corp

UTHR

UTHR: United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

more

Show UTHR Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of UTHR by members of U.S. Congress

Politician Type Traded
Donna Shalala House / D Sale $1,001 - $15,000 Mar. 06, 2019
Thomas Macarthur House / R Sale $1,001 - $15,000 May. 27, 2015
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by UTHR's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $40,000 Jan 19, 2010 Issue: Pharmacy Defense Homeland Security Science/Technology
  • $50,000 Oct 19, 2009 Issue: Pharmacy Defense Homeland Security Science/Technology
  • $40,000 Jul 20, 2009 Issue: Science/Technology Homeland Security Defense Pharmacy
  • $40,000 Apr 15, 2009 Issue: Science/Technology Pharmacy Defense Homeland Security
  • $40,000 Jan 16, 2009 Issue: Defense Pharmacy Homeland Security Science/Technology
U.S. Patents

New patents grants

  • Patent Title: Treatment for interstitial lung disease Aug. 22, 2023
  • Patent Title: Process to prepare treprostinil, the active ingredient in remodulin® Aug. 15, 2023
  • Patent Title: Enhanced solubility drug-containing formulations Jun. 13, 2023
  • Patent Title: Treprostinil prodrugs Jun. 13, 2023
  • Patent Title: Treatment of pulmonary arterial hypertension with mesenchymal stem cells Jun. 06, 2023
  • Patent Title: Treprostinil prodrugs Apr. 25, 2023
  • Patent Title: Size-efficient drug-delivery device Feb. 07, 2023
  • Patent Title: Enhancement of msc immunomodulatory properties by treprostinil Feb. 07, 2023
  • Patent Title: Synthesis of esuberaprost prodrugs Jan. 24, 2023
  • Patent Title: Drug delivery device Jan. 03, 2023
  • Patent Title: Aerosol delivery device and method for manufacturing and operating the same Jul. 05, 2022
  • Patent Title: Treprostinil administration by inhalation Jun. 14, 2022
  • Patent Title: Compounds and methods for delivery of prostacyclin analogs Apr. 05, 2022
  • Patent Title: Salts of treprostinil Feb. 01, 2022
  • Patent Title: Synthesis of intermediates for producing prostacyclin derivatives Jan. 18, 2022
  • Patent Title: Treatment of vasculopathy with prostacyclin and mesenchymal stem cells Oct. 12, 2021
  • Patent Title: Controlled release pharmaceutical formulations May. 11, 2021
  • Patent Title: Compounds and methods for delivery of prostacyclin analogs Mar. 16, 2021
  • Patent Title: Extracellular vesicles with enhanced potency Mar. 16, 2021
  • Patent Title: Method for purifying antibodies Feb. 02, 2021
  • Patent Title: Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells Nov. 24, 2020
  • Patent Title: Dosage inhaler Oct. 20, 2020
  • Patent Title: Aerosol delivery device and method for manufacturing and operating the same Oct. 13, 2020
  • Patent Title: Synthesis of intermediates for producing prostacyclin derivatives Sep. 15, 2020
  • Patent Title: Automated bioreactor system, system for automatically implementing protocol for decellularizing organ, and waste decontamination system Sep. 01, 2020
  • Patent Title: Treprostinil administration by inhalation Jul. 21, 2020
  • Patent Title: Inhalation formulations of treprostinil Jun. 30, 2020
  • Patent Title: Process to prepare treprostinil, the active ingredient in remodulin® Feb. 04, 2020
  • Patent Title: Controlled release pharmaceutical formulations Dec. 03, 2019
  • Patent Title: Process to prepare treprostinil, the active ingredient in remodulin® Nov. 19, 2019
  • Patent Title: Treprostinil administration by inhalation Aug. 13, 2019
  • Patent Title: Process to prepare treprostinil, the active ingredient in remodulin® Jun. 18, 2019
  • Patent Title: Synthesis of intermediates for producing prostacyclin derivatives Feb. 05, 2019
  • Patent Title: Solid forms of treprostinil Jan. 01, 2019
  • Patent Title: Osmotic drug delivery system Dec. 18, 2018
  • Patent Title: Process for making beraprost Oct. 09, 2018
  • Patent Title: Treatment of vasculopathy with prostacyclin and mesenchymal stem cells Sep. 25, 2018
  • Patent Title: Synthesis of intermediate for treprostinil production Sep. 18, 2018
  • Patent Title: Inhalation formulations of treprostinil Sep. 18, 2018
  • Patent Title: Treatment of pulmonary arterial hypertension with mesenchymal stem cells Sep. 11, 2018
  • Patent Title: Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells Jul. 10, 2018
  • Patent Title: Salts of treprostinil Jun. 05, 2018
  • Patent Title: Compounds and methods for delivery of prostacyclin analogs Jan. 30, 2018
  • Patent Title: Solid forms of treprostinil Nov. 21, 2017
  • Patent Title: Process for making beraprost Sep. 19, 2017
  • Patent Title: Controlled release pharmaceutical formulations Sep. 12, 2017
  • Patent Title: Parenteral formulations of treprostinil Jul. 25, 2017
  • Patent Title: Salts of treprostinil Jul. 11, 2017
  • Patent Title: Compounds and methods for delivery of prostacyclin analogs Apr. 18, 2017
  • Patent Title: Synthesis of intermediate for treprostinil production Apr. 04, 2017
Government Contracts

Federal grants, loans, and purchases

WallStreetBets

Number of mentions of UTHR in WallStreetBets Daily Discussion

UTHR News

Recent insights relating to UTHR

CNBC Recommendations

Recent picks made for UTHR stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in UTHR

Corporate Flights

Flights by private jets registered to UTHR